Physician profile
Saint Adeogba
NPI 1265587869
$6,366.13
in general payments reported to CMS, 2019-2025
37 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $1,567 · 2021: $2,172 · 2022: $1,114 · 2023: $99.90 · 2024: $66.66 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,789.52 | 2021-2022 | |
| Boston Scientific Corporation | $1,267.86 | 2019-2023 | |
| Spr Therapeutics, INC | $605.77 | 2022 | |
| Collegium Pharmaceutical, INC. | $270.74 | 2019-2022 | |
| Lilly USA, LLC | $244.93 | 2019-2022 | |
| Allergan, INC. | $212.04 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $176.89 | 2019-2021 | |
| Amgen INC. | $169.92 | 2019-2022 | |
| Mdd US Operations, LLC | $164.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.42 | 2019-2022 | |
| Abbvie INC. | $155.93 | 2021-2024 | Qulipta |
| Horizon Therapeutics Plc | $147.47 | 2019-2022 | |
| Abbott Laboratories | $139.52 | 2019-2025 | Eterna |
| Piramal Critical Care | $107.33 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $106.18 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $80.13 | 2019-2020 | |
| Stimwave Technologies Incorporated | $55.55 | 2019 | |
| Merz Pharmaceuticals, LLC | $52.00 | 2025 | Xeomin |
| Redhill Biopharma INC. | $48.23 | 2021 | |
| Nalu Medical, INC. | $44.19 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.26 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $35.70 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $33.82 | 2025 | |
| Daiichi Sankyo INC. | $31.53 | 2019 | |
| Scilex Pharmaceuticals INC. | $30.36 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $26.23 | 2020-2021 | |
| Averitas Pharma INC. | $24.75 | 2023 | Qutenza |
| Grt US Holding, INC. | $19.28 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.19 | 2019 | |
| Novo Nordisk INC | $16.52 | 2022 | |
| Avanos Medical | $16.25 | 2022 | |
| Globus Medical, INC. | $15.47 | 2025 | Senza |
| Alexion Pharmaceuticals, INC. | $12.38 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.80 | 2020 | |
| Kaleo, INC. | $11.76 | 2019 | |
| Pfizer INC. | $11.51 | 2019 | |
| Vgi Medical, LLC | $7.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saint Adeogba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.